AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's

Drugs from the burgeoning JAK group have so far run into their fair share of safety liabilities, and if the label for new AbbVie med Rinvoq is any indication, the FDA now believes those issues are class-wide.